bioRxivCell Biology
Interferon-gamma and TNF-alpha synergistically enhance the immunomodulatory capacity of Endometrial-Derived Mesenchymal Stromal Cell secretomes by differential microRNA and extracellular vesicle release
M. d. l. A. de Pedro, F. Marinaro, E. Lopez, M. Pulido, F. M. Sanchez Margallo, V. Alvarez, J. G Casado
Abstract
Endometrial Mesenchymal Stromal Cells (endMSCs) can be easily isolated from menstrual blood by plastic adherence. These cells have a potent pro-angiogenic and immunomodulatory capacity, and their therapeutic effect is mediated by paracrine mechanisms where secretome have a key role. In this paper, we aimed to evaluate different priming conditions in endMSCs using pro-inflammatory cytokines and Toll-Like Receptor ligands. Our in vitro results revealed a synergistic and additive effect of IFN{gamma} and TNF on endMSCs. The combination of these pro-inflammatory cytokines significantly increased the release of Indoleamine 2,3-dioxygenase (IDO1) in endMSCs. Additionally, this study was focused on the phenotype of IFN{gamma}/TNF-primed endMSCs (endMSCs*). Here we found that immune system-related molecules such as CD49d, CD49e, CD54, CD56, CD58, CD63, CD126, CD152, or CD274 were significantly altered in endMSCs* when compared to control cells. Afterward, our study was completed with the characterization of released miRNAs by Next Generation Sequencing (NGS). Briefly, our system biology approaches demonstrated that endMSCs* showed an increased release of 25 miRNAs whose target genes were involved in immune response and inflammation. Finally, the cellular and molecular characterization was completed with in vitro functional assays. In summary, the relevance of our results lies in the therapeutic potential of endMSCs*. The differences in cell surface molecules involved in migration, adhesion and immunogenicity, allowed us to hypothesize that endMSCs* may have an optimal homing and migration capacity towards inflammatory lesions. Secondly, the analysis of miRNAs, target genes and the subsequent lymphocyte activation assays demonstrated that IFN{gamma}/TNF-primed secretome may exert a potent effect on the regulation of adverse inflammatory reactions.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Licensing Microgels Prolong the Immunomodulatory Phenotype of Mesenchymal Stromal Cells
M. Patrick, R. T. Annamalai·bioRxiv·Jul 5, 2022
- Extracellular Vesicle-Enriched Secretome from Mesenchymal Stromal Cells Protects Against Chemically, Particulate-, and Ischemia-Induced Innate-Immunity Induced Inflammation
Kyong‐Su Park, Negar Ordouzadeh, … Massimo Dominici·bioRxiv·Apr 13, 2026
- Sphingomyelinase Licensing of Mesenchymal Stromal Cells Alters Lipid and Protein Metabolites for Immunomodulation
S’Dravious A. DeVeaux, Daniel C. Shah, … Edward A. Botchwey·bioRxiv·Jul 17, 2025
- Priming of MSCs with inflammation-relevant signals affects extracellular vesicle biogenesis, surface markers, and modulation of T cell subsets
S. H. Andrews, T. Maughon, … S. L. Stice·bioRxiv·Apr 30, 2020
- Persistent tailoring of MSC activation through genetic priming
M. A. Beauregard, G. C. Bedford, … M. R. Diehl·bioRxiv·Feb 1, 2024
- Morphological Landscapes from High Content Imaging Identify Optimal Priming Strategies that Enhance MSC Immunosuppression
S. H. Andrews, M. W. Klinker, … R. A. Marklein·bioRxiv·Feb 23, 2021